Monte Rosa Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	297	283	368	950	-	-
Market Cap Growth	-	-23.18%	-61.22%	-	-	-
Enterprise Value	111	97	152	604	-43	-8
PE Ratio	-2.09	-2.09	-3.39	-12.84	-	-
PB Ratio	1.66	1.58	1.36	2.73	-	-
P/FCF Ratio	-4.51	-4.51	-3.50	-13.76	-	-
P/OCF Ratio	-6.46	-6.46	-3.98	-16.00	-	-
EV/EBITDA Ratio	-0.75	-0.75	-1.52	-8.40	1.21	1.11
EV/EBIT Ratio	-0.72	-0.72	-1.40	-8.16	1.19	1.10
EV/FCF Ratio	-1.54	-1.54	-1.44	-8.75	1.62	1.12
Debt / Equity Ratio	0.26	0.26	0.17	-	-	-0.06
Debt / EBITDA Ratio	-0.36	-0.36	-0.47	-	-	-0.10
Debt / FCF Ratio	-0.73	-0.73	-0.45	-	-	-0.10
Quick Ratio	5.00	5.00	10.62	20.80	1.46	2.15
Current Ratio	5.07	5.07	10.79	20.96	1.49	2.27
Return on Equity (ROE)	-65.90%	-65.90%	-36.50%	-29.20%	117.90%	-
Return on Assets (ROA)	-47.30%	-47.30%	-30.80%	-22.80%	-118.70%	-
Return on Capital (ROIC)	-63.61%	-63.61%	-35.29%	-20.97%	57.48%	70.14%
Earnings Yield	-45.59%	-47.83%	-29.46%	-7.79%	-	-
FCF Yield	-21.14%	-22.19%	-28.58%	-7.27%	-	-
Buyback Yield / Dilution	-8.83%	-8.83%	-88.91%	-1548.09%	69.66%	-
Total Shareholder Return	-8.83%	-8.83%	-88.91%	-1548.09%	69.66%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).